Skip to content

A multicenter, prospective, randomized controlled study of the effect of radical hysterectomy and radical concurrent chemoradiotherapy on the prognosis of locally advanced (IB3, IIA2, IIICr) cervical cancer

A multicenter, prospective, randomized controlled study of the effect of radical hysterectomy and radical concurrent chemoradiotherapy on the prognosis of locally advanced (IB3, IIA2, IIICr) cervical cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041315
Enrollment
Unknown
Registered
2020-12-23
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

1:Radical hysterectomy
2:Concurrent chemotherapy and radiotherapy

Sponsors

Obstetrics and Gynecology Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients clinically diagnosed with locally advanced cervical cancer: IB3, iia2, iiicr (only suspected lymph node positive by imaging); 2. Patients with preoperative pathological diagnosis of cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma; 3. Patients whose age is less than or equal to 70 years old; 4. Physical strength grade: Karnofsky score >= 60; 5. The patients who were treated for the first time; 6. The patients who volunteered to join the study signed informed consent, good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients who can't accept surgery because of various surgical contraindications; 2. Patients who received pelvic / abdominal radiotherapy or chemotherapy in the past; 3. Patients with distant metastasis indicated by CT, MRI or pet; 4. Preoperative imaging and physical examination showed that there was no parametrial involvement, no extension to the pelvic wall, and no involvement in the lower third of vagina.

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival;Overall survival;

Secondary

MeasureTime frame
Complications;Quality of life;

Countries

China

Contacts

Public ContactKeqin Hua

Obstetrics and Gynecology Hospital Affiliated to Fudan University

huakeqin@fudan.edu.cn+86 15921515900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026